Management of Advanced and Relapsed/Refractory Extra-Nodal Natural Killer T-Cell Lymphoma (ENKL): An Analysis of Stem Cell Transplant and Chemotherapy Outcomes

Extra-nodal natural killer/T-cell lymphoma (ENKL) is a rare lymphoma representing approximately 5-10% of T-cell non-Hodgkin lymphomas diagnosed in the United States each year.1, 2 ENKL is universally associated with Epstein-Barr virus (EBV) infection, and is more frequent in Asian, Central American and South American populations, where it constitutes 5-15% of all lymphomas.3-5 Patients with advanced stage ENKL (stage III-IV) and relapsed/refractory early stage disease are treated with systemic chemotherapy with or without radiotherapy.

Source: Clinical Lymphoma, Myeloma and Leukemia - October 11, 2017 Category: Hematology Authors: Jonathan E. Brammer, Dai Chihara, L. Michelle Poon, Paolo Caimi, Marcos de Lima, Celina Ledesma, Gabriela Rondon, Stefan O. Ciurea, Yago Nieto, Michele Fanale, Bouthaina Dabaja, Richard T. Maziarz, Richard E. Champlin, Chitra Hosing, Yasuhiro Oki Source Type: research